These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 25342898

  • 1. Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.
    ZuWallack R, Allen L, Hernandez G, Ting N, Abrahams R.
    Int J Chron Obstruct Pulmon Dis; 2014; 9():1133-44. PubMed ID: 25342898
    [Abstract] [Full Text] [Related]

  • 2. The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies.
    Ichinose M, Taniguchi H, Takizawa A, Grönke L, Loaiza L, Voß F, Zhao Y, Fukuchi Y.
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2017-27. PubMed ID: 27621608
    [Abstract] [Full Text] [Related]

  • 3. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.
    Koch A, Pizzichini E, Hamilton A, Hart L, Korducki L, De Salvo MC, Paggiaro P.
    Int J Chron Obstruct Pulmon Dis; 2014; 9():697-714. PubMed ID: 25045258
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life.
    Singh D, Ferguson GT, Bolitschek J, Grönke L, Hallmann C, Bennett N, Abrahams R, Schmidt O, Bjermer L.
    Respir Med; 2015 Oct; 109(10):1312-9. PubMed ID: 26320402
    [Abstract] [Full Text] [Related]

  • 6. Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.
    Halpin DM, Dahl R, Hallmann C, Mueller A, Tashkin D.
    Int J Chron Obstruct Pulmon Dis; 2015 Oct; 10():239-59. PubMed ID: 25709423
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
    Sauer R, Hänsel M, Buhl R, Rubin RA, Frey M, Glaab T.
    Int J Chron Obstruct Pulmon Dis; 2016 Oct; 11():891-8. PubMed ID: 27217742
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease.
    Ichinose M, Takizawa A, Izumoto T, Tadayasu Y, Hamilton AL, Kunz C, Fukuchi Y.
    Int J Chron Obstruct Pulmon Dis; 2015 Oct; 10():1673-83. PubMed ID: 26316741
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of tiotropium-olodaterol fixed-dose combination in COPD.
    Derom E, Brusselle GG, Joos GF.
    Int J Chron Obstruct Pulmon Dis; 2016 Oct; 11():3163-3177. PubMed ID: 28008243
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by age.
    Ferguson GT, Karpel JP, Clerisme-Beaty E, Grönke L, Voß F, Buhl R.
    Int J Chron Obstruct Pulmon Dis; 2016 Oct; 11():2701-2710. PubMed ID: 27843306
    [Abstract] [Full Text] [Related]

  • 13. The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes.
    Anzueto A, Wise R, Calverley P, Dusser D, Tang W, Metzdorf N, Dahl R.
    Respir Res; 2015 Sep 15; 16(1):107. PubMed ID: 26369563
    [Abstract] [Full Text] [Related]

  • 14. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
    Beeh KM, Derom E, Echave-Sustaeta J, Grönke L, Hamilton A, Zhai D, Bjermer L.
    Int J Chron Obstruct Pulmon Dis; 2016 Sep 15; 11():193-205. PubMed ID: 26893551
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis.
    Ferguson GT, Fležar M, Korn S, Korducki L, Grönke L, Abrahams R, Buhl R.
    Adv Ther; 2015 Jun 15; 32(6):523-36. PubMed ID: 26112656
    [Abstract] [Full Text] [Related]

  • 16. Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch.
    Hanada S, Wada S, Ohno T, Sawaguchi H, Muraki M, Tohda Y.
    Int J Chron Obstruct Pulmon Dis; 2015 Jun 15; 10():69-77. PubMed ID: 25609941
    [Abstract] [Full Text] [Related]

  • 17. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies.
    Singh D, Gaga M, Schmidt O, Bjermer L, Grönke L, Voß F, Ferguson GT.
    Respir Res; 2016 Jun 18; 17(1):73. PubMed ID: 27316465
    [Abstract] [Full Text] [Related]

  • 18. Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease.
    Ramadan WH, Kabbara WK, El Khoury GM, Al Assir SA.
    Int J Chron Obstruct Pulmon Dis; 2015 Jun 18; 10():2347-56. PubMed ID: 26586940
    [Abstract] [Full Text] [Related]

  • 19. A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease.
    Maleki-Yazdi MR, Beck E, Hamilton AL, Korducki L, Koker P, Fogarty C.
    Respir Med; 2015 May 18; 109(5):596-605. PubMed ID: 25829298
    [Abstract] [Full Text] [Related]

  • 20. Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease.
    Aalbers R, Maleki-Yazdi MR, Hamilton A, Waitere-Wijker S, Zhao Y, Amatto VC, Schmidt O, Bjermer L.
    Adv Ther; 2015 Sep 18; 32(9):809-22. PubMed ID: 26404912
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.